-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Their immune rheumatism (ARD) whether the patient has a high SARS-CoV 2- infection risk ( COVID-19 ), and the impact of SARS-CoV-2 pandemic on treatment compliance has not yet been fully elucidated.
Immune infection COVID-19
Between April 9 and April 25, 2020, after the peak of SARS-CoV-2 infection, researchers conducted a telephone survey to investigate the effects of COVID-19 on systemic lupus erythematosus (SLE), systemic lupus erythematosus (SLE), and systemic lupus erythematosus (SLE).
Rheumatoid arthritis blood vessels
In the end, 916 patients (397 systemic lupus erythematosus patients, 182 AAV patients, 176 SSc patients, 111 RA patients, and 50 IIM patients) completed the investigation.
In summary, the results of the study show that the incidence of COVID-19 in the study cohort is similar to that of the general population.
Original source:
M Zen, E Fuzzi, et al.
ncbi.
nlm.
nih.
gov/32527675/" target="_blank" rel="noopener">SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients in this message